000			02185cam a2200313 a 4500
003			EG-GiCUC
008			150518s2014 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2014.Mo.P
100	0		_aMohamed Hodhod Elsayed Mohamed Aboumanei
245	1	0	_aPharmaceutical formulation of some radiolabeled pharmaceutical compounds for possible use as a model in cancer imaging and therapy / _cMohamed Hodhod Elsayed Mohamed Aboumanei ; Supervised Ahmed Abdelbary , Mohamed Taha Hussein Elkolaly
246	1	5	_aالصياغة الصيدلية لبعض المركبات الصيدلانيه المرقمه اشعاعيا لإمكانية إستخدامها كنموذج فى تصوير وعلاج السرطان
260			_aCairo : _bMohamed Hodhod Elsayed Mohamed Aboumanei , _c2014
300			_a172 P. : _bcharts , facsimiles ; _c30cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aEarly detection of cancer through screening based on imaging is probably the major contributor to a reduction in mortality for certain cancers. Targeted imaging or therapy of receptors, gene therapy expression and cancer stem cells are research activities that will translate into clinical use in the next decade. The use of various contrast agents and radiotracers for cancer imaging and therapy are reviewed, as are the current limitations of ultrasound, x-ray imaging, and magnetic resonance imaging (MRI), and single-photon emission computed tomography, positron emission tomography (PET), and optical imaging. The lack of selectivity of chemotherapeutic anticancer agent also is still a serious drawback in conventional cancer chemotherapy
530			_aIssued also as CD
653		4	_aCancer imaging and therapy
653		4	_aPharmaceutical formulation
653		4	_aRadiolabeled pharmaceutical compounds
700	0		_aAhmed Abdelbary , _eSupervisor
700	0		_aMohamed Taha Hussein Elkolaly , _eSupervisor
905			_aNazla _eRevisor
905			_aSoheir _eCataloger
942			_2ddc _cTH
999			_c50969 _d50969